Shares of Achaogen Inc (NASDAQ:AKAO) have received a consensus rating of “Buy” from the twelve analysts that are currently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $21.17.
A number of equities research analysts have recently commented on AKAO shares. ValuEngine upgraded shares of Achaogen from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Zacks Investment Research downgraded shares of Achaogen from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Wedbush reiterated an “outperform” rating and set a $22.00 price target (down from $28.00) on shares of Achaogen in a report on Wednesday, February 14th. William Blair reiterated an “outperform” rating on shares of Achaogen in a report on Wednesday, February 28th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Achaogen in a report on Sunday, March 4th.
In other Achaogen news, major shareholder Robert W. Duggan acquired 102,849 shares of the firm’s stock in a transaction on Friday, April 27th. The stock was bought at an average cost of $12.96 per share, for a total transaction of $1,332,923.04. Following the completion of the purchase, the insider now directly owns 7,028,153 shares in the company, valued at $91,084,862.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Robert W. Duggan acquired 976,880 shares of the firm’s stock in a transaction on Thursday, May 3rd. The shares were acquired at an average price of $11.33 per share, with a total value of $11,068,050.40. Following the completion of the purchase, the insider now owns 8,027,627 shares of the company’s stock, valued at $90,953,013.91. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 1,878,674 shares of company stock valued at $22,666,809. 7.80% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AKAO. Stifel Financial Corp purchased a new stake in Achaogen during the first quarter worth approximately $134,000. MetLife Investment Advisors LLC acquired a new position in shares of Achaogen during the fourth quarter worth $151,000. Ellington Management Group LLC acquired a new position in shares of Achaogen during the fourth quarter worth $177,000. Tower Research Capital LLC TRC lifted its position in shares of Achaogen by 375.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock worth $201,000 after purchasing an additional 14,725 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of Achaogen during the first quarter worth $207,000. Institutional investors own 68.72% of the company’s stock.
Achaogen traded down $0.03, reaching $11.92, during midday trading on Monday, according to Marketbeat. 15,898 shares of the company’s stock were exchanged, compared to its average volume of 1,208,936. The company has a current ratio of 7.01, a quick ratio of 7.01 and a debt-to-equity ratio of 0.24. The stock has a market cap of $539.79 million, a P/E ratio of -3.82 and a beta of 0.96. Achaogen has a 1-year low of $9.83 and a 1-year high of $25.22.
Achaogen (NASDAQ:AKAO) last announced its earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.17). The business had revenue of $2.14 million for the quarter, compared to analyst estimates of $1.25 million. Achaogen had a negative return on equity of 97.86% and a negative net margin of 2,384.08%. analysts forecast that Achaogen will post -3.43 EPS for the current fiscal year.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.